MethylGene Inc, a biopharmaceutical company, today announced operational and financial results for the first quarter ended March 31, 2006. Highlights: Signed a research, development and commercialization agreement with Pharmion Corporation, a deal worth potentially up to US$272 million, for MethylGene's oncology HDAC inhibitors, including MGCD0103, for North America, Europe and other territories. CCN Matthews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&searchText=false&showText=all&actionFor=593063)
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Devicemakers Pay $9.5 Million for Selling Uncleared Products
The FDA hit Instrumed with a warning letter in 2014.
Federal Circuit Won’t Rehear Purdue Pharma’s OxyContin Patent Claims
The U.S. Court of Appeals for the Federal Circuit turned down Purdue’s appeal and upheld the PTAB ruling.
